Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

2.650 +0.030 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 332,636
Open 2.630
Bid (Size) 2.560 (3,000)
Ask (Size) 2.680 (500)
Prev. Close 2.620
Today's Range 2.590 - 2.730
52wk Range 0.4900 - 3.620
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+71.0%
+71.0%
1 Month
+15.7%
+15.7%
3 Month
+103.8%
+103.8%
6 Month
+173.5%
+173.5%
1 Year
+333.0%
+333.0%

More News

Read More
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
From Equity Insider
Via GlobeNewswire
News headline image
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress ↗
Via Chartmill
News headline image
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Chief Medical Officer Transition
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
From Context Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Context Therapeutics Inc. - Common Stock publicly traded?
Yes, Context Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Context Therapeutics Inc. - Common Stock trade on?
Context Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Context Therapeutics Inc. - Common Stock?
The ticker symbol for Context Therapeutics Inc. - Common Stock is CNTX on the Nasdaq Stock Market
What is the current price of Context Therapeutics Inc. - Common Stock?
The current price of Context Therapeutics Inc. - Common Stock is 2.650
When was Context Therapeutics Inc. - Common Stock last traded?
The last trade of Context Therapeutics Inc. - Common Stock was at 04/01/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.